EUVIMEDEUVIMED entdecken
Leitlinie

Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update

Jennifer Y Wo, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Nader Hanna, Maria Hawkins, Michael Holtz, Edward Kim, Patrick Kelly, Diane C Ling, Jeffrey R Olsen und 6 weitere

Practical Radiation Oncology · 2025-03 · 15 (2) · 124-143

DOI: 10.1016/j.prro.2024.11.003 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Practical Radiation Oncology, 2025-03. Verfasst von Jennifer Y Wo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: JWO@mgh.harvard.edu. Hauptthemen laut MEDLINE: Rectal Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: American Society for Radiation Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation. RESULTS: For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node-positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus and based on disease extent, disease location, patient preferences, and quality of life considerations. CONCLUSIONS: The task force proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsHumansNeoadjuvant Therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: JWO@mgh.harvard.edu.
  • Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
  • Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • American Society for Radiation Oncology, Arlington, Virginia.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

Förderung

  • American Society for Radiation Oncology

Zitieren

APA

Wo, J. Y., Ashman, J. B., Bhadkamkar, N. A., Bradfield, L., Chang, D. T., Hanna, N., Hawkins, M., Holtz, M., Kim, E., Kelly, P., Ling, D. C., Olsen, J. R., Palta, M., Raldow, A. C., Ruiz-Garcia, E., Sheybani, A., Stitzenberg, K. B., & Das, P. (2025). Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. Practical Radiation Oncology, 15(2), 124-143. https://doi.org/10.1016/j.prro.2024.11.003

Vancouver

Wo JY, Ashman JB, Bhadkamkar NA, Bradfield L, Chang DT, Hanna N, et al. Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. Practical Radiation Oncology. 2025;15(2):124-143. doi:10.1016/j.prro.2024.11.003

BibTeX
@article{Wo2025,
  author = {Wo, Jennifer Y and Ashman, Jonathan B and Bhadkamkar, Nishin A and Bradfield, Lisa and Chang, Daniel T and Hanna, Nader and Hawkins, Maria and Holtz, Michael and Kim, Edward and Kelly, Patrick and Ling, Diane C and Olsen, Jeffrey R and Palta, Manisha and Raldow, Ann C and Ruiz-Garcia, Erika and Sheybani, Arshin and Stitzenberg, Karyn B and Das, Prajnan},
  title = {Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update},
  journal = {Practical Radiation Oncology},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {124--143},
  doi = {10.1016/j.prro.2024.11.003}
}
Kostenlos starten →